Supplemental Imaging for Breast Implants with Obscured Tissue on Mammography
In a patient with breast implants whose mammogram shows obscured tissue, you should order targeted hand-held ultrasound (HHUS) rather than ABUS as your next imaging step.
Rationale and Clinical Approach
Why Ultrasound Over ABUS in This Context
The evidence specifically addressing breast implants indicates that ultrasound is the primary supplemental modality when mammography is limited 1, 2. While ABUS has been studied for supplemental screening in dense breasts, the guidelines consistently recommend hand-held ultrasound for implant-related evaluation because:
- Implant obscuration is a mechanical problem, not just a density issue - The implant physically blocks visualization of breast tissue, which differs from the tissue overlap seen in dense breasts
- Targeted evaluation is needed - You need to assess specific areas obscured by the implant, which requires the flexibility and real-time assessment of hand-held technique
- ABUS has significant limitations in this population - The European guidelines explicitly recommend against implementing ABUS for supplemental screening even in dense breasts due to very low certainty of evidence, increased recall rates, and lack of mortality benefit 3
The Evidence Against ABUS
The 2020 European Breast Guidelines provide the strongest recent guidance: ABUS after negative mammography increased cancer detection but also increased recall rates, with no evidence of mortality benefit 3. The guideline development group determined that "the balance of health effects favors neither ABUS after mammography nor mammography alone" and recommended against implementing ABUS in organized screening programs 3.
The 2025 ACR Appropriateness Criteria acknowledge that while ABUS can detect additional cancers (3.0 per 1,000 in dense tissue), this comes at the cost of low biopsy positive predictive values and high false-positive rates 4.
Specific Recommendations for Implant Patients
For patients ≥40 years old with implants:
- Perform diagnostic mammography with Eklund/displaced views (implant pushed back to maximize tissue visualization) 2
- Add targeted hand-held ultrasound to evaluate areas obscured by the implant 1, 2
- Ultrasound can characterize palpable lumps and evaluate nonpalpable lesions detected on mammography 2
For patients <40 years old with implants:
- Ultrasound is the primary imaging modality 1
- Mammography may not be indicated unless there are specific clinical concerns
When to Consider MRI Instead
If ultrasound yields indeterminate or equivocal results, MRI without and with IV contrast becomes the appropriate next step 1. MRI is particularly valuable for:
- Detecting peri-implant tissue abnormalities
- Evaluating suspected implant rupture with extracapsular extension
- High-risk patients where ultrasound is insufficient
Critical Pitfalls to Avoid
- Don't order ABUS reflexively for "dense breasts" - Implant obscuration requires targeted evaluation, not automated screening
- Don't skip the Eklund views - Proper mammographic technique with implant displacement should be attempted first
- Don't rely on mammography alone - Studies show 22-83% of glandular tissue can be obscured by implants 5
- Don't order MRI as first-line supplemental imaging - Reserve this for equivocal ultrasound findings or high-risk scenarios 1
The Bottom Line
Order targeted hand-held breast ultrasound to evaluate the areas obscured by the implant. This provides real-time, operator-directed assessment of specific regions of concern and allows for immediate correlation with any palpable findings. ABUS is not appropriate in this clinical scenario as it was designed for supplemental screening in dense breasts, not for problem-solving in implant patients where tissue is mechanically obscured 3, 1, 2.